BioInsights - Cell Therapy Materials & Upstream Processing/Analytics - spotlight

CELL AND GENE THERAPY INSIGHTS

March 2023

Cell Therapy Materials & Upstream Processing/Analytics

Download PDF

Expert Insight

Challenges in obtaining cellular therapy starting material for patients with sickle cell disease

Challenges in obtaining cellular therapy starting material for patients with sickle cell disease

Yvette C Tanhehco

Innovator Insight

Implementing a closed cell therapy manufacturing process through strategic collaboration

Implementing a closed cell therapy manufacturing process through strategic collaboration

Ø Åmellem, X Mollerat du Jeu, B Shy

Commentary

Overcoming challenges to CAR-T cell therapies in India

Overcoming challenges to CAR-T cell therapies in India

A Uppal, R Chakrabarti, N Chirmule et al.

Interview

Ensuring success in working with apheresis centers

Ensuring success in working with apheresis centers

Suzanne Kamps

Bridging the knowledge gap in donor cellular starting material quality & variability

Bridging the knowledge gap in donor cellular starting material quality & variability

FastFacts

Increase quality & standardization of cellular starting material

Increase quality & standardization of cellular starting material

Matt Hemstreet

Viewpoint

Distributed manufacturing models for ATMPs: can they work: do we understand the pitfalls?

Distributed manufacturing models for ATMPs: can they work: do we understand the pitfalls?

Mark Lowdell

Webinars

Pain points to potential: Positioning process and analytical development for next-gen cell therapies

Pain points to potential: Positioning process and analytical development for next-gen cell therapies

Sarah Campion, Alex Sargent

Improve your speed to therapy and drive efficiency by integrating supply chain and manufacturing

Improve your speed to therapy and drive efficiency by integrating supply chain and manufacturing

Robert Lutskus, Matthew Lakelin

Scale-up and deliver allogeneic cell therapies to large patient populations

Scale-up and deliver allogeneic cell therapies to large patient populations

M Langtry, K Panchalingam, I Friedrich Ben-Nun

Overcoming challenges to succeed when transitioning into a cGMP environment

Overcoming challenges to succeed when transitioning into a cGMP environment

Kris Wronski

Cell therapy manufacturing and 21 CFR Part 11 compliance: Overview and considerations for instrument software

Cell therapy manufacturing and 21 CFR Part 11 compliance: Overview and considerations for instrument software

Ashley Smith, Brianna Volk

Navigating bottlenecks in cell therapy manufacturing: A versatile and scalable platform solution

Navigating bottlenecks in cell therapy manufacturing: A versatile and scalable platform solution

Peter Yates